Fosamax and Osteonecrosis of the Jaw: Risk and Causation Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Communication

The legacy of general health and science information has long served as a foundation for public understanding of medication risks, emphasizing broad awareness and patient education. Within this tradition, the transition from general health contexts to specific exposure concerns requires careful attention to how established knowledge frameworks can be adapted. Historically, the dissemination of health information has focused on accessible communication of scientific findings, enabling individuals to make informed decisions about their well-being. This heritage provides a robust platform for examining more targeted questions, such as those arising from pharmaceutical exposure. As we pivot from this general context, the focus narrows to the relationship between bisphosphonate use and oral health complications, particularly in populations with prolonged exposure. The shift from broad health literacy to occupational exposure concern is marked by a change in perspective: rather than addressing the general public, attention turns to specific groups who may face heightened risk due to repeated or sustained contact with these compounds. This pivot does not alter the commitment to evidence-based communication but refines the lens through which risk is assessed. By building on the legacy of clear, accessible health information, we can now explore how exposure patterns—especially in occupational settings—inform our understanding of potential adverse outcomes, maintaining the same rigor and neutrality that characterized earlier public health messaging.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax. ONJ is characterized by exposed bone in the maxillofacial region that does not heal within eight weeks, often occurring spontaneously or following dental procedures. Clinical presentation and diagnosis of ONJ typically involve delayed healing after tooth extraction, local infection, or spontaneous exposure of necrotic bone. The condition is generally associated with invasive dental procedures, local infection, or trauma (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Evidence Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits osteoclast-mediated bone resorption. This suppression of bone turnover can impair the jawbone's ability to remodel and repair microdamage, particularly in response to dental procedures or infection. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique structure and high remodeling rate may make it particularly susceptible to the effects of bisphosphonate accumulation. Regarding the timeline between exposure and documented health outcomes, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Population Studies and Risk Quantification

A population-based cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides evidence of a dose-response relationship between duration of bisphosphonate exposure and ONJ risk, supporting a causal link. In safety-communication contexts, the FDA has included warnings about ONJ in the prescribing information for Fosamax. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that known risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies, poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For affected patients, causation-focused clinical interpretation requires consideration of the temporal relationship between Fosamax exposure and ONJ onset, the presence of known risk factors, and the exclusion of other causes. The evidence supports that Fosamax can cause ONJ, particularly with longer duration of use and in the presence of dental procedures or other risk factors. However, the absolute risk remains low, and the benefits of Fosamax in reducing fracture risk must be weighed against the potential for ONJ. Patients should be informed about the signs and symptoms of ONJ, such as jaw pain, swelling, or non-healing sores, and advised to maintain good oral hygiene and undergo regular dental check-ups. For those requiring invasive dental procedures, a drug holiday may be considered to reduce risk. In summary, studies show a consistent association between Fosamax use and ONJ, with evidence of a dose-response relationship and plausible biological mechanisms. The risk is low but increases with longer exposure and in the presence of additional risk factors. Clinical management should focus on risk mitigation through dental care and consideration of treatment duration.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ), a condition where the jawbone fails to heal after minor trauma or dental procedures. Studies show a dose-response relationship, with risk increasing with longer use. The FDA has included warnings in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and co-morbid disorders like periodontal disease. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in Fosamax users?

Absolute risk is low, approximately 0.05% after 5 years of use. However, risk increases with duration: threefold after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.